BIOTRON

Biotron Limited (Biotron) is a clinical stage publicly listed Australian Biotechnology Company based in Sydney, Australia. The company is developing and commercialising a novel small molecule approach that has the potential to treat a number of serious viral diseases. The technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus (RSV)... Biotron is developing a unique class of small molecule therapeutics that target viral-encoded viroporin proteins... Biotron's viroporin approach has also demonstrated early in vitro activity against virus such as Dengue & Zika, with early stage development continuing in a range of viruses.

Also known as: Biotron Limited

Registration numbers: 60 086 399 144 (W)

Primary location: Sydney Australia